Kazia Therapeuti Stock Price, News & Analysis

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company based in Sydney, Australia. According to company disclosures and regulatory filings, Kazia is a clinical-stage biotechnology company developing pharmaceutical drug candidates for the treatment of cancer, with a particular emphasis on brain cancers and advanced breast cancer. The company is listed on The Nasdaq Capital Market via American Depositary Shares (ADSs).

Kazia’s business centers on discovering, in-licensing, and clinically developing targeted therapies that address areas of high unmet medical need in oncology. The company describes itself as an oncology-focused drug development company and a clinical-stage biotechnology company, reflecting that its primary assets are in clinical and preclinical development rather than on-market commercial products.

Core Programs and Pipeline

The company’s lead program is paxalisib, described in multiple company announcements as an investigational, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is being developed to treat multiple forms of cancer, with a strong focus on brain cancers such as glioblastoma and other primary and secondary tumors involving the central nervous system. Company materials state that paxalisib has been, or is, the subject of ten clinical trials in this disease area.

Kazia reports that a Phase 2/3 study in glioblastoma (GBM-Agile) has been completed, with results reported in 2024, and that discussions are ongoing regarding the design and execution of a pivotal registrational study aimed at pursuing a standard approval pathway in newly diagnosed glioblastoma. Additional clinical trials involving paxalisib are described as ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data.

In advanced breast cancer, Kazia highlights a Phase 1b clinical trial evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer (TNBC). Company news releases also describe ex vivo and early clinical data in HER2-positive metastatic breast cancer and TNBC, including reductions in circulating tumor cells (CTCs) and CTC clusters, epigenetic reprogramming of tumor cells, and changes in immune cell phenotypes. These findings are presented by the company as supportive of paxalisib’s potential role in disrupting metastatic biology and enhancing anti-tumor immunity when used alongside immunotherapies.

Kazia also reports that paxalisib has received multiple regulatory designations from the U.S. Food and Drug Administration (FDA). These include Orphan Drug Designation for glioblastoma, Fast Track Designation for glioblastoma, Fast Track Designation for solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy, and Rare Pediatric Disease and Orphan Drug Designations for diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumors. These designations, as described in company communications, relate to specific indications and are intended to facilitate development in defined patient populations.

Beyond paxalisib, Kazia is developing EVT801, a small molecule inhibitor of VEGFR3 that the company licensed from Evotec SE. Company announcements state that preclinical data have shown EVT801 to be active against a broad range of tumor types and to exhibit evidence of synergy with immuno-oncology agents. A Phase I study of EVT801 in advanced solid tumors has been completed, with preliminary data presented at a scientific meeting in ovarian cancer research.

In addition, Kazia has entered into an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader program. The lead optimized compound, referred to as NDL2, is described as an advanced PD-L1 protein degrader representing a new frontier of cancer immunotherapy. According to company and SEC disclosures, the program will initially target advanced breast cancer and non-small cell lung cancer (NSCLC), particularly in settings where resistance to existing PD-1/PD-L1 immunotherapies is common. IND-enabling studies are expected by the company to commence within a defined timeframe, with a goal of progressing toward first-in-human studies, and Kazia has indicated its intention to explore combinations of NDL2 with paxalisib and EVT801.

Scientific and Clinical Focus

Kazia’s scientific strategy, as described in its news releases, emphasizes targeting signaling pathways and immunologic mechanisms that drive tumor growth, metastasis, and resistance to existing therapies. Paxalisib is characterized as a brain-penetrant pan-PI3K/mTOR or PI3K / Akt / mTOR pathway inhibitor, and the company highlights its activity in brain cancers and metastatic breast cancer settings where circulating tumor cell clusters and immune exhaustion are important features of disease biology.

Company communications describe mechanistic work showing that paxalisib can reduce single CTCs and disrupt CTC clusters in HER2-positive metastatic breast cancer ex vivo, and that in TNBC settings it may contribute to epigenetic reprogramming of tumor cells and reinvigoration of exhausted T cells. These findings are framed by Kazia as supportive of paxalisib’s potential to address resistance mechanisms and to complement checkpoint inhibitors such as pembrolizumab in combination regimens.

Through participation in initiatives such as an Australian Medical Research Future Fund (MRFF) project for diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), Kazia also positions paxalisib within broader efforts to integrate targeted therapies with AI-enabled decision platforms. In that project, the company provides paxalisib as one of several brain-penetrant small molecules to be evaluated in preclinical models and incorporated into an AI-guided therapeutic sequencing framework.

Regulatory and Capital Markets Context

Kazia files as a foreign private issuer with the U.S. Securities and Exchange Commission (SEC) on Form 20-F and Form 6-K. The company’s filings describe its status as a clinical-stage biotechnology or oncology-focused drug development company and outline its financing activities, including private placements of equity securities, at-the-market offerings of ADSs, and related registration statements.

In 2025, the company reported receiving a notice from Nasdaq regarding non-compliance with the Market Value of Listed Securities requirement, followed by a staff determination letter indicating potential suspension or delisting absent a hearing. Subsequent SEC filings and press releases describe private placements intended to strengthen stockholders’ equity and the company’s belief that, following a significant private placement, it had stockholders’ equity in excess of the minimum requirement for continued listing under an alternative Nasdaq standard. A later press release states that Nasdaq confirmed Kazia had regained compliance with all applicable listing requirements and that its ADSs would continue to trade on The Nasdaq Capital Market.

These capital markets activities are presented by the company as supporting continued development of its lead programs, including paxalisib, EVT801, and the PD-L1 degrader program, as well as general corporate purposes.

Geographic Footprint and Collaborations

Company disclosures and SEC filings identify Kazia Therapeutics Limited as based in Sydney, New South Wales, Australia, with its principal executive office located in that city. The Polygon description and company announcements also reference operations in Australia and the United States, reflecting that its clinical and regulatory activities span multiple jurisdictions.

Kazia engages in collaborations and licensing arrangements with academic and research institutions such as QIMR Berghofer and Evotec SE, as well as participation in consortia supported by entities like the Australian Medical Research Future Fund. These collaborations are focused on advancing specific assets (such as NDL2 and EVT801) and integrating the company’s investigational drugs into broader translational research and clinical strategies.

Position Within the Pharmaceutical and Biotechnology Sector

Within the broader pharmaceutical preparation manufacturing and biotechnology landscape, Kazia positions itself as a company focused on targeted oncology drug development, particularly in brain cancers and advanced breast cancer. Its pipeline, as described in company materials, spans small molecule inhibitors of key signaling pathways (PI3K/Akt/mTOR and VEGFR3) and a protein degrader targeting PD-L1. The company emphasizes regulatory designations, clinical trial activity in high-need indications, and mechanistic data related to tumor biology and immune modulation.

Because Kazia’s programs remain in clinical and preclinical stages, revenue generation from product sales is not described in the provided materials. Instead, the company’s value proposition, as presented in its own disclosures, is tied to the potential of its investigational assets to progress through clinical development and, subject to regulatory review, to reach commercialization in defined oncology indications.

FAQs about Kazia Therapeutics Limited (KZIA)

• What does Kazia Therapeutics Limited do?
  Kazia Therapeutics Limited is an oncology-focused drug development and clinical-stage biotechnology company. It develops investigational therapies for cancer, with a primary focus on brain cancers and advanced breast cancer, based on targeted small molecules and protein degraders.
• What is Kazia’s lead drug candidate?
  The company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is being developed to treat multiple forms of cancer, including glioblastoma, other brain tumors, and advanced breast cancer.
• In which indications is paxalisib being studied?
  According to company announcements, paxalisib has been or is being studied in glioblastoma through the GBM-Agile Phase 2/3 study, as well as in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, across multiple clinical trials.
• What regulatory designations has paxalisib received?
  Kazia reports that paxalisib has received Orphan Drug Designation for glioblastoma, Fast Track Designation for glioblastoma and for certain solid tumor brain metastases with PI3K pathway mutations in combination with radiation therapy, and Rare Pediatric Disease and Orphan Drug Designations for diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumors.
• What is EVT801?
  EVT801 is a small molecule inhibitor of VEGFR3 that Kazia licensed from Evotec SE. Company materials state that EVT801 has shown preclinical activity across a range of tumor types and evidence of synergy with immuno-oncology agents, and that a Phase I clinical study in advanced solid tumors has been completed with preliminary data presented at a scientific conference.
• What is the PD-L1 degrader program (NDL2)?
  Through an agreement with QIMR Berghofer, Kazia has in-licensed a first-in-class PD-L1 protein degrader program. The lead compound, NDL2, is described as an advanced PD-L1 degrader intended to target resistant, post-translationally modified forms of PD-L1 in cancers such as advanced breast cancer and non-small cell lung cancer, with IND-enabling studies planned by the company.
• Where is Kazia Therapeutics based and on which exchange does it trade?
  Kazia Therapeutics Limited is based in Sydney, Australia. Its American Depositary Shares, each representing ordinary shares of the company, trade on The Nasdaq Capital Market under the ticker symbol KZIA.
• What is Kazia’s role in pediatric brain cancer research?
  Kazia participates in an Australian Medical Research Future Fund project focused on diffuse midline glioma and diffuse intrinsic pontine glioma, providing its investigational drug paxalisib as part of a therapeutic toolkit evaluated within an AI-enabled clinical decision platform. Paxalisib has also received Rare Pediatric Disease and Orphan Drug Designations for certain pediatric brain tumor indications.
• How does Kazia fund its development programs?
  SEC filings describe that Kazia has used private placements of equity securities, at-the-market offerings of ADSs, and other financing arrangements to raise capital. The company states that proceeds are intended to support clinical development of paxalisib, EVT801, the PD-L1 degrader program, and general corporate purposes.
• Has Kazia faced any Nasdaq listing compliance issues?
  In 2025, Kazia reported receiving notices from Nasdaq regarding non-compliance with the Market Value of Listed Securities requirement. Following private placements and related actions, the company later announced that it had regained full compliance with all applicable Nasdaq listing standards and that its ADSs would continue to trade on The Nasdaq Capital Market.